Article info
Correspondence response
Response to: ‘Comment on: ‘Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis’ by Sabbagh S et al’ by Yang et al
- Correspondence to Dr Andrew Lee Mammen, NIAMS/NIH, Bethesda, MD 20892, USA; andrew.mammen{at}nih.gov
Citation
Response to: ‘Comment on: ‘Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis’ by Sabbagh S et al’ by Yang et al
Publication history
- Received May 30, 2019
- Revised June 3, 2019
- Accepted June 4, 2019
- First published June 17, 2019.
Online issue publication
May 15, 2023
Article Versions
- Previous version (15 May 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.